Biotech · Public company · Chicago, IL, US
Exicure, Inc.
Ticker XCUR · SEC CIK 0001698530
Track this companyFree. Adds Exicure, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline3
- CavrotolimodPhase 2 · Advanced or Metastatic Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CemiplimabPhase 2 · Advanced or Metastatic Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Advanced or Metastatic Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid TumorsPHASE1_PHASE2 · TERMINATED · started Dec 13, 2018ClinicalTrials.gov NCT03684785 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 16, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 1, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 27, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 17, 2026 · fetched Nov 12, 2026